Browsing by Author Boddy, Alan

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 20 of 23  next >
Issue DateTitleAuthor(s)Citation
2015Age-Dependent Pharmacokinetics of Doxorubicin in Children with CancerBoddy, Alan; Boos, Joachim; Hempel, Georg; Kontny, Nina E; Krischke, Miriam; Voller, Swantje; Wurthwein, Gudrun; PharmacyAge-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer, Clinical Pharmacokinetics, vol.54, 11, 2015,pp 1139-1149
2016Calpain-1 is associated with adverse relapse free survival in breast cancer: A confirmatory studyBoddy, Alan; Ahmad, Narmeen; Chan, Stephen; Cresti, Nicola; Ellis, Ian; Martin, Stewart; Moseley, Paul; Pu, Xuan; Storr, Sarah; Televantou, Despina; PharmacyCalpain-1 is associated with adverse relapse free survival in breast cancer: A confirmatory study, Histopathology, vol.68, 7, 2016,pp 1021-1029
2017Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactionsAdiwidjaja, Jeffry; Boddy, Alan; McLachlan, Andrew; Pharmacy; Pharmacy; PharmacyCurcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions, Expert Opinion on Drug Metabolism and Toxicology, vol.13, 9, 2017,pp 953-972
2016Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphomaBoddy, Alan; Chamberlain, Thomas; Chinnaswamy, Girish; Cole, Michael; Errington, J; Hill, Christopher R; Jamieson, David; Malik, Ghada; Sludden, Julieann; Veal, G; PharmacyCyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma, European Journal of Cancer, vol.55, N/A, 2016,pp 56-64
2016Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphomaBoddy, Alan; Chamberlain, Thomas; Chinnaswamy, Girish; Cole, Michael; Errington, J; Hill, Christopher R; Jamieson, David; Malik, Ghada; Sludden, Julieann; Veal, G; PharmacyCyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma, European Journal of Cancer, vol.55, N/A, 2016,pp 56-64
2016Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancerBoddy, Alan; Bonner, Jennifer; Ghazaly, Essam; Gribben, John; Johnson, Trevor; Neuhoff, Sibylle; Veal, G; Walsh, Christopher; PharmacyDevelopment of a physiologically based pharmacokinetic model of actinomycin D in children with cancer, British Journal of Clinical Pharmacology, vol.81, 5, 2016,pp 989-998
2016Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancerBoddy, Alan; Bonner, Jennifer; Ghazaly, Essam; Gribben, John; Johnson, Trevor; Neuhoff, Sibylle; Veal, G; Walsh, Christopher; PharmacyDevelopment of a physiologically based pharmacokinetic model of actinomycin D in children with cancer, British Journal of Clinical Pharmacology, vol.81, 5, 2016,pp 989-998
2015Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung CancerBoddy, Alan; Chan, Kim; Chrzanowski, Wojciech; Kim, Sally; Bishop, David; Doble, Philip; Kundu, Subhas; Naskar, Deboki; Wall, Ivan; Pharmacy; Pharmacy; Pharmacy; PharmacyFormulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer, Scientific Reports, vol.5, N/A, 2015,pp 1-13
2016Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?Boddy, Alan; Curtin, Nicola J; Hutton, Claire; Jamieson, David; McPherson, Stuart; Ogle, Laura F; Orr, James G; Plummer, Ruth; Reeves, Helen; Willoughby, Catherine E; PharmacyImagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?, Journal of Hepatology, vol.65, 2, 2016,pp 305-313
2016The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitorsBoddy, Alan; Liu, Xiaoman; Low, Siew Kee; Pharmacy; Pharmacy; PharmacyThe implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors, Expert Opinion on Drug Metabolism and Toxicology, vol.12, 8, 2016,pp 851-863
2017Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study)Boddy, Alan; Anderson, J. R.; Dirksen, U.; et al, Various; Fresneau, Brice; Hackshaw, A.; Hawkins, Douglas S; Judson, Ian R.; Lewis, I.; Litiere, S.; Paulussen, M.; PharmacyInvestigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study), Pediatric Blood & Cancer, vol.64, 8, 2017,pp 1-8
2016Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumoursBoddy, Alan; Galettis, Peter T; Goulooze, Sebastian C; Martin, Jennifer; PharmacyMonte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours, Cancer Chemotherapy and Pharmacology, vol.78, 1, 2016,pp 209-216
2016Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumoursBoddy, Alan; Galettis, Peter T; Goulooze, Sebastian C; Martin, Jennifer; PharmacyMonte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours, Cancer Chemotherapy and Pharmacology, vol.78, 1, 2016,pp 209-216
2017Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamideBoddy, Alan; Allan, James; Cresti, Nicola; Griffin, Melanie; Jamieson, David; Lee, Johanne; Muro, Sara; Pouche, Lucie; Sludden, Julieann; Sunter, Nicola; Verrill, Mark W; PharmacyPharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide, European Journal of Cancer, vol.71, N/A, 2017,pp 15-24
2016Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trialBoddy, Alan; Andre, Nicolas; Bisogno, Gianni; Boos, Joachim; Borowski, Matthias; D'Incalci, Maurizio; Hempel, Georg; Herold, Ralf; Kopcke, Wolfgang; Krischke, Miriam; Voller, Swantje; PharmacyPharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial, Cancer Chemotherapy and Pharmacology, vol.78, 6, 2016,pp 1175-1184
2017Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysisBoddy, Alan; Carlino, Matteo; Harris, David; Lee, Vincent; Liu, Xiao man; Kefford, Richard; Park, J; Pharmacy; Western Clinical School: Medicine (Westmead); Western Clinical School: Westmead Institute for Medical Res; Western Clinical School: Medicine (Westmead); PharmacyPharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis, Pigment Cell & Melanoma Research, vol.30, 1, 2017,pp 68-71
2016Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancerBoddy, Alan; Acton, Gary; Backholer, Zoe; Curtin, Nicola J; Drew, Yvette; Glasspool, Rosalind; Halford, Sarah; Hall, Geoff D.; Highley, Martin S.; Jamieson, David; Jayson, G. C.; Ledermann, Jonathan; Mangano, Raffaella; Murray, James; Plummer, Ruth; Rea, Daniel William; Sludden, Julieann; PharmacyPhase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer, British Journal of Cancer, vol.114, 7, 2016,pp 723-730
2016A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumoursBoddy, Alan; Allen, Rodger A.; Anthoney, Alan; Banerji, Udai; Bevan, Paul B.; Buerkle, Markus; Coyle, V. M.; Cresti, Nicola; Dean, Emma; Drew, Yvette; Evans, T. R Jeffery; Greystoke, Alastair P.N.; Griffin, Melanie; Jamieson, David; Mala, Carola; Merriman, Mark W.; Plummer, Ruth; Ranson, Malcolm R.; Rodgers, Lisa; Sludden, Julieann; Swales, Karen E.; Wilson, Richard; PharmacyA phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours, European Journal of Cancer, vol.68, 1, 2016,pp 1-10
2016Plasma Retinol Kinetics and (beta)-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A StoresBoddy, Alan; Berry, Philip; Ford, Jennifer Lynn; Green, Joanne Balmer; Green, Michael H.; Lietz, George; Oxley, Anthony; Park, Hyunjin; PharmacyPlasma Retinol Kinetics and (beta)-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores, The Journal of Nutrition, vol.146, 10, 2016,pp 2129-2136
2017A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemiaBoddy, Alan; Duong, Janna; Edwards, D; Griffin, Melanie; Hargrave, Darren R.; Vormoor, J; Pharmacy; PharmacyA population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia, British Journal of Clinical Pharmacology, vol.83, 8, 2017,pp 1713-1722